Prolira is a cutting-edge brand that specializes in the early detection and monitoring of acute encephalopathy and delirium. With their innovative DeltaScan® Brain State Monitor, they offer a rapid and objective measurement of these conditions, enabling timely interventions for improved patient outcomes. This device provides high diagnostic value and can significantly enhance healthcare for older patients.

Acute encephalopathy and delirium are major postoperative complications among older adults, affecting up to 50% of surgical and ICU patients in Europe and the US each year. Shockingly, up to 88% of delirious patients go unnoticed in daily clinical practice. Prolira aims to change that by incorporating quantitative brain data into the diagnostic process through the DeltaScan® Brain State Monitor.

Prolira has achieved significant milestones, including exclusive licensing from the University Medical Center Utrecht and conducting three successful clinical studies with 434 patients. The device is CE-certified according to EU MDR since 2020 and has received FDA clearance since 2023. Prolira is open to clinical and strategic partnerships to further advance the care for acute encephalopathy and delirium.

Stay informed about the latest news and upcoming events from Prolira DeltaScan® and join them in their mission to improve healthcare outcomes for patients suffering from acute encephalopathy and delirium. Sources: American Geriatric Society, Inouye et al. 2014, Marcantonio et al.

N Engl J Med 2017